In Wednesday's early morning trading session shares are gaining 0.28% to $57.87.
"We view Merck's outlook as solid though not compelling enough at this time to warrant anything other than a neutral," analysts said.
The next four years should show a much improved earnings trend compared with the recent past, however, the revenue challenges are such that the pipeline needs to work even harder to generate a more dynamic top-line, analysts added.
What has been positive is management's efforts so shake-up the R&D organization and sell the consumer health business, according to the analysts note.
Separately, TheStreet Ratings team rates MERCK & CO as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
"We rate MERCK & CO (MRK) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income."